Apellis Pharmaceuticals Inventory Over Time
| APLS Stock | USD 22.58 0.47 2.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Apellis Pharmaceuticals Performance and Apellis Pharmaceuticals Correlation. Is there potential for Biotechnology market expansion? Will Apellis introduce new products? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.35 | Revenue Per Share | Quarterly Revenue Growth 1.33 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apellis Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apellis Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apellis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Inventory Analysis
Compare Apellis Pharmaceuticals and related stocks such as Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, and Mineralys Therapeutics Inventory Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPRX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 56 K | 2 M | 4.7 M | 7.9 M | 6.8 M | 15.6 M | 19.5 M | 22.5 M | 23.6 M |
| KNSA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 M | 21.6 M | 31.1 M | 26.4 M | 30.3 M | 18.2 M |
| BEAM | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (607.4 M) | (546.6 M) | (574 M) |
| CDTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (321 K) | (5.5 M) | (5.5 M) | (2.6 M) | (2.6 M) | 1.0 | 6.1 M | 6.1 M | 7 M | 7.4 M |
| ADPT | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 7.8 M | 9.1 M | 14.1 M | 19.3 M | 14.5 M | 14.4 M | 8.4 M | 9.7 M | 12.7 M |
| SRRK | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (25 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.1 M) | (3.3 M) |
| IDYA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (121.3 M) | (121.3 M) | (121.3 M) | (8.3 M) | 532.6 M | 532.6 M | 612.5 M | 643.1 M |
| AGIO | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | (58.9 M) | (32.2 M) | (143.8 M) | 869 K | 7.3 M | 14.7 M | 16.2 M | 8.5 M | 19.1 M | 27.6 M | 31.8 M | 33.3 M |
| RXRX | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5 M | 1.6 M | 1.3 M | (3.1 M) | (3.1 M) | (2.8 M) | (2.6 M) |
Apellis Pharmaceuticals and related stocks such as Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, and Mineralys Therapeutics Inventory description
My Equities
My Current Equities and Potential Positions
| Apellis Pharmaceuticals | APLS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Fifth Avenue, |
| Exchange | NASDAQ Exchange |
USD 22.58
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.